Skip to main navigation
  • Investors & News
    • Investors Overview
    • Press Releases
    • Events
    • Governance
    • Financial Information
    • Stock Information
    • FAQs
    • Contact Us
  • Careers
  • Contact Us
  • Share
logo
  • About Omeros
    • About Omeros
    • Leadership
  • Science
    • Research Areas
    • Discovery Technologies
    • Scientific
      Publications
  • Pipeline
    • Pipeline Overview
    • OMIDRIA®
    • Narsoplimab
      (OMS721)
    • OMS824
    • OMS405
    • OMS527
    • OMS906
    • MASP-2, MASP-3,
      MASP-2/3
    • GPR174
    • GPR161
  • Patients
    • Commitment
      to Patients
  • Search
  • Investors & News
    • Investors Overview
    • Press Releases
    • Events
    • Governance
    • Financial Information
    • Stock Information
    • FAQs
    • Contact Us
  • Careers
  • Contact Us
  • Share

Investor Relations

  • Press Releases
  • Events
    • Upcoming Events
    • Archived Events
  • Governance
    • Highlights
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financial Information
    • Quarterly Results
    • Annual Reports
    • Proxy Statements
    • SEC Filings
    • Analyst Coverage
    • Presentations & Documents
  • Stock Information
    • Stock Quote
    • Stock Chart
    • Historical Prices
    • Investment Calculator
  • FAQs
  • Contact Us

SEC Filing Details

SEC Filing Details

Document Details

Form
10-K
Filing Date
Mar 1, 2021
Document Date
Dec 31, 2020
Form Description
Annual report which provides a comprehensive overview of the company for the past year
Filing Group
Annual Filings
Company
Omeros Corporation
Issuer
OMEROS CORP

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.CAL - EX-101.CAL
EX-101.DEF - EX-101.DEF
EX-101.LAB - EX-101.LAB
EX-101.PRE - EX-101.PRE
XML - XBRL INSTANCE DOCUMENT

Omeros logo©2023 Omeros Corporation, All rights reserved.

  • Site Map
  • Contact Us
  • Privacy Policy
  • Legal

  • Investors & News
    • Investors Overview
    • Press Releases
    • Events
    • Governance
    • Financial Information
    • Stock Information
    • FAQs
    • Contact Us
  • Careers
  • Contact Us
  • Share
  • About Omeros
    • About Omeros
    • Leadership
  • Science
    • Research Areas
    • Discovery Technologies
    • Scientific
      Publications
  • Pipeline
    • Pipeline Overview
    • OMIDRIA®
    • Narsoplimab
      (OMS721)
    • OMS824
    • OMS405
    • OMS527
    • OMS906
    • MASP-2, MASP-3,
      MASP-2/3
    • GPR174
    • GPR161
  • Patients
    • Commitment
      to Patients

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. If you continue to browse this site, you will accept our use of cookies. For more information, please read our Privacy Policy.
Agree

You are now leaving Omeros.com

Omeros makes no representation as to the accuracy of the information on sites we do not own or control and does not recommend or endorse content on any third-party websites. Your use of a third-party website is at your own risk and subject to the terms and conditions of that site.

Continue

© 2023 Omeros All rights reserved